Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market

Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).

Read More »

Ardelyx’s Tenapanor Hits the Mark in CKD Trial

Ardelyx’s Phase III AMPLIFY study of tenapanor achieved the clinical trial’s primary endpoint, as well as all key secondary endpoints, in treating patients with chronic kidney disease (CKD).

Read More »

Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of Linzess in Adults with IBS-C

Ironwood Pharmaceuticals Inc. and Allergan plc announced positive topline data from a Phase IIIb clinical trial evaluating Linzess 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C).

Read More »

FDA Approves First-Ever Indication for Device for Patients With Functional Abdominal Pain Associated With IBS

Innovative Health Solutions Inc. announced FDA clearance for the new device IB-Stim to treat functional abdominal pain associated with irritable bowel syndrome (IBS) in patients ages 11-18 years old.

Read More »

Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals

Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into.

Read More »

Ad-ventures in Marketing XI

For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.

Read More »

FDA Approves Trulance for IBS-C in Adults

Synergy Pharmaceuticals Inc. announced that the U.S. FDA approved Trulance (plecanatide) 3-mg tablet for the once-daily treatment of irritable bowel syndrome with constipation in adults.

Read More »

Drugmakers raise 2018 U.S. prices

2018 opened with elevated U.S. prices on dozens of medicines, but early data showed the increases generally remained within a 10 percent self-imposed limit.

Read More »

Five Biotechs Awaiting FDA Decisions in January 2018

Here are five companies looking at possible drug approvals in January 2018.

Read More »

Pfizer Takes Stake in Rhythm Pharmaceuticals

Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom